IMARC Group, a leading market research company, has recently releases report titled “Antipsychotic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032,” The study provides a detailed analysis of the industry, including the global antipsychotic drugs market share, size, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the antipsychotic drugs market?
The global antipsychotic drugs market size reached US$ 16.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 28.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.
Factors Affecting the Growth of the Antipsychotic Drugs Industry:
- Rising prevalence of mental health disorders:
Conditions such as schizophrenia, bipolar disorder, and major depressive disorder are affecting millions of people worldwide, necessitating effective pharmacological interventions to manage symptoms and improve patient's quality of life. Antipsychotic medications are crucial in treating psychotic symptoms such as hallucinations, delusions, and disorganized thinking associated with these disorders. As awareness about mental health grows and diagnostic capabilities improve, the demand for antipsychotic drugs continues to rise, particularly in regions where mental health services are expanding, thereby creating a positive outlook in the market growth.
- Advancements in drug development:
Pharmaceutical companies are investing heavily in research and development (RD) to innovate new antipsychotic agents with improved efficacy, fewer side effects, and novel mechanisms of action. These advancements include the development of second-generation antipsychotics that offer advantages over older first-generation drugs, such as reduced risk of extrapyramidal symptoms and better tolerability. In addition to this, ongoing research focuses on personalized medicine approaches to tailor treatment based on genetic and biomarker profiles, potentially enhancing therapeutic outcomes and patient adherence, thus bolstering the market growth.
- Expanding the application of antipsychotic drugs:
There is an expanding application of antipsychotic drugs beyond schizophrenia. Although it was originally developed to treat psychosis associated with schizophrenia, antipsychotics are increasingly prescribed for other psychiatric conditions, including bipolar disorder, major depressive disorder with psychotic features, and treatment-resistant depression. These drugs are also used off-label to manage symptoms in conditions such as autism spectrum disorders and dementia-related psychosis. The versatility of antipsychotic medications in treating a spectrum of psychiatric symptoms across various healthcare settings, including hospitals, outpatient clinics, and residential care facilities, aiding the market growth.
Request for a sample copy of this report: https://www.imarcgroup.com/antipsychotic-drugs-market/requestsample
Antipsychotic Drugs Market Report Segmentation:
Breakup By Therapeutic Class:
- First Generation
- Haldol
- Navane
- Others
- Second Generation
- Invega
- Latuda
- Seroquel
- Risperdal
- Zyprexa
- Geodon
- Others
- Third Generation
- Abilify
Second-generation antipsychotics account for the majority of shares due to their improved safety profile and efficacy in treating psychiatric disorders.
Breakup By Application:
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
Schizophrenia represents the majority of shares, as antipsychotic drugs are primarily prescribed to manage the symptoms associated with this disorder.
Breakup By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Retail pharmacies dominate the market because they provide convenient access for patients to fill prescriptions and access ongoing medication management.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position due to its high prevalence of mental health disorders, advanced healthcare infrastructure, and extensive pharmaceutical market penetration.
Global Antipsychotic Drugs Market Trends:
The increasing awareness and acceptance of mental health treatment, coupled with initiatives to reduce stigma and improve access to psychiatric care, is providing an impetus to the market expansion. Besides this, the expansion of telepsychiatry and digital health platforms, which facilitate remote consultations and medication management for psychiatric conditions, enhances patient access to treatment, supporting the adoption of antipsychotic medications globally. Furthermore, increasing recognition of the link between mental health and physical health, prompting integrated care approaches that emphasize the role of antipsychotics in managing comorbid conditions like cardiovascular diseases and diabetes, and expanding their therapeutic applications is contributing to the market expansion.
Who are the key players operating in the industry?
The report covers the major market players including:
- AbbVie Inc.
- Alkermes plc
- Dr. Reddy’s Laboratories Ltd.
- Johnson Johnson
- Otsuka Pharmaceutical Co. Ltd.
- Viatris Inc.
Browse the full report with TOC and list of Figures: https://www.imarcgroup.com/request?type=reportid=19329flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
